Whole-Body MRI Metastatic Staging Protocol: 10 Critical Steps for Radiographers and Radiologists

Introduction: why whole-body MRI staging matters

Whole-body MRI metastatic staging has moved from a niche academic pursuit to a mainstream oncologic imaging pathway in little more than a decade, and the reason is straightforward: it stages disease across the entire skeleton and soft tissues in a single non-ionizing examination, without the cumulative radiation burden of repeated CT or bone scintigraphy. For patients with multiple myeloma, lymphoma, prostate cancer, breast cancer, and neuroblastoma, whole-body MRI now sits alongside PET/CT as a first-line or complementary staging tool, and in myeloma, whole-body MRI is explicitly recommended over skeletal survey radiography by international consensus groups.^[1]

The clinical case for whole-body MRI is strongest wherever repeated imaging is anticipated. A patient newly diagnosed with multiple myeloma may undergo baseline staging, a response assessment after induction therapy, a further check before stem-cell transplantation, and periodic surveillance thereafter — potentially five or more whole-body examinations within two years. Achieving that cadence with serial low-dose CT or bone scintigraphy carries a cumulative radiation burden that becomes clinically material over a young patient’s remaining lifetime, whereas an MRI-based pathway carries none. This single feature — the ability to repeat the examination as often as the clinical picture demands, without a radiation ledger to balance — is arguably the strongest driver behind the adoption of whole-body MRI across oncology departments over the past decade.

Two broad acquisition philosophies exist. The step-and-shoot approach, most common on 1.5T systems, indexes the table to a discrete position, halts, acquires a full set of sequences at that station, then advances to the next station and repeats. The continuously moving table approach synchronises table motion with data acquisition so that k-space is filled as the patient glides through the bore, producing a near-seamless dataset for certain sequence types, though STIR and DWI in most current clinical implementations still rely on the step-and-shoot method because of their reliance on discrete inversion and diffusion-gradient timing. Recognising which approach a given scanner platform uses is essential before troubleshooting any stitching artefact, because the failure modes differ meaningfully between the two.

The technical premise is deceptively simple: move the patient through the magnet bore in discrete table positions, or use a continuously moving table, and stitch the resulting images into one composite dataset spanning skull vertex to mid-thigh (or toes, for full staging). In practice, achieving diagnostic-quality stitched images across five to seven stations, each with its own coil sensitivity profile, shim volume, and gradient linearity envelope, is one of the more demanding technical exercises in the MRI department.

The rapid growth in whole-body MRI utilisation has also been accompanied by growing consensus around standardised acquisition and reporting frameworks, first in myeloma with MY-RADS and subsequently extended, with modality-specific adaptations, to prostate cancer (MET-RADS-P) and other solid-tumour metastatic pathways. These frameworks exist precisely because early, unstandardised whole-body MRI practice produced inconsistent protocols and reporting language across centres, undermining the comparability of serial examinations for a given patient over time — a problem this article’s emphasis on structured technique and reporting, discussed later, is designed to prevent.

This protocol focuses on the metastatic staging indication: skeletal and nodal survey for known or suspected malignancy, most commonly multiple myeloma, lymphoma, and diffuse skeletal metastatic disease from breast, prostate, and other solid tumours. Day 27 of the MRI Protocol Mastery Series builds on the multi-station and moving-table concepts introduced in the peripheral runoff MRA protocol (Day 26), but trades angiographic bolus tracking for STIR/DWI oncologic contrast — a fundamentally different technical challenge centred on geometric fidelity rather than temporal fidelity.

Whole-body MRI staging occupies a unique niche among the 30 protocols in this series because it is the only examination that is intentionally designed to be non-contrast by default. Understanding when and why gadolinium is selectively added — and why the vast majority of staging examinations proceed without it — is central to running this protocol efficiently and safely across a busy oncology imaging list.

Anatomy: the whole-body field of coverage

Unlike every other protocol in this series, whole-body MRI staging does not target a single organ system — it targets the entire axial and appendicular skeleton, the lymph node chains, and, depending on protocol extent, selected solid organs. Radiographers and radiologists must therefore hold a systematic mental map of the anatomy traversed by each table station rather than a single anatomical region.

Skeletal coverage

The standard staging field of view extends from the vertex of the skull to the mid-thigh (the “MY-RADS” myeloma-focused extent) or to the ankles/feet for a full metastatic survey in tumours with a predilection for distal appendicular spread, such as some sarcomas and certain paediatric malignancies. Coverage includes the calvarium, facial skeleton, mandible, cervical/thoracic/lumbar spine, ribs, sternum, clavicles, scapulae, pelvis, and proximal and distal long bones. Red (haematopoietically active) marrow is concentrated in the axial skeleton and proximal femora/humeri in adults, while yellow (fatty) marrow predominates in the distal appendicular skeleton — a distinction fundamental to interpreting STIR signal.

The distribution of red and yellow marrow is not static across a patient’s lifespan, and this has direct protocol implications. At birth, essentially the entire skeleton contains red marrow; conversion to yellow marrow proceeds in a predictable centripetal pattern through childhood and adolescence, beginning distally in the hands and feet and progressing proximally, so that by early adulthood red marrow is normally confined to the axial skeleton, pelvis, and proximal femoral/humeral metaphyses. A radiographer or radiologist unfamiliar with this pattern may misinterpret persistent red marrow in a young adult’s proximal femora as pathological, when it in fact represents entirely normal physiology for that age group. Reviewing the patient’s age alongside the marrow distribution pattern is therefore a routine and necessary step before any STIR hyperintensity is flagged as suspicious.

Nodal and soft-tissue coverage

Cervical, axillary, mediastinal, hilar, retroperitoneal, mesenteric, and inguinal nodal chains fall within the field of view at their respective table stations. Solid organ coverage (liver, spleen, kidneys) is incidental on STIR/DWI but becomes diagnostic when the optional post-infusion T1 Dixon station is added, most often for lymphoma staging where splenic and hepatic infiltration must be assessed alongside nodal disease.

Systematic nodal review benefits from working through each chain in a consistent cranio-caudal order at every examination, rather than scanning opportunistically for whichever nodes appear most conspicuous on the STIR or DWI-MIP overview. A consistent review order reduces the risk of overlooking a subtle abnormality in a less frequently involved chain, such as the epitrochlear or popliteal nodal groups, which are easy to omit from a cursory review but occasionally harbour disease in specific lymphoma subtypes.

Station boundaries as anatomical landmarks

Each table station is typically 40–50 cm in the superior-inferior direction, meaning five to seven stations are required for full coverage in an average adult. The technologist must recognise that station boundaries do not respect anatomical structures — a station edge frequently bisects the mid-thorax or mid-femur — which is precisely why overlap and stitching accuracy at these boundaries becomes the single most important technical variable in the entire examination.

In practice, the most technically demanding boundary is usually the one crossing the diaphragm, where respiratory motion, coil sensitivity roll-off, and the transition from thoracic to abdominal tissue composition all coincide. The pelvis-to-thigh boundary presents a different challenge: the femoral heads and proximal shafts sit at the periphery of gradient linearity in many bore geometries, making this junction particularly prone to the geometric distortion discussed later in this article. Departments that habitually struggle with a specific boundary should audit whether that junction consistently falls at an anatomically complex transition rather than assuming the fault lies with a single acquisition parameter.

MR tissue relaxation values

Because whole-body staging interrogates marrow, nodal tissue, and multiple solid organs simultaneously, relaxation values must be considered across tissue types rather than for a single organ. The table below summarises approximate values at 1.5T, which remain the most widely validated field strength for WB-MRI marrow assessment.

The diagnostic power of STIR in whole-body staging derives directly from the T1 gap between normal yellow marrow and infiltrated marrow: STIR nulls fat signal via inversion recovery timed to the T1 of fat, so any marrow replaced by tumour — which has a longer T1 and therefore is not nulled — stands out as focal or diffuse hyperintensity against a uniformly dark background.

It is worth noting that the relaxation values above represent population averages measured under standardised conditions, and real patient values will vary with age, hydration status, recent chemotherapy, and individual marrow composition. This variability is precisely why whole-body staging relies on a qualitative signal-pattern approach (focal versus diffuse, STIR-bright with corresponding T1-dark, low ADC) rather than attempting to set fixed numerical relaxation thresholds for a positive finding, in contrast to some other protocols in this series where quantitative HU or ADC cutoffs are more directly applicable.

Scanning technique: the 10-step protocol

Executing a whole-body staging examination well requires the radiographer to think in terms of a pipeline rather than a single acquisition: preparation and coil bridging happen once, but shimming, sequence acquisition, and quality checks repeat at every station, and a small inefficiency at step 4 or step 5 below is multiplied five to seven times across the full examination. The sequence of steps below reflects the order in which most departments organise the workflow, from patient preparation through to final stitched quality review.

1. Patient preparation and positioning. Position the patient supine, arms at the sides (or overhead if bore diameter and coil bridging allow) to minimise lateral aliasing and reduce arm-related susceptibility. Confirm fasting status is not required (unlike PET/CT) and confirm no recent bone marrow stimulating therapy (G-CSF) within the preceding 5–7 days, since this transiently increases marrow cellularity and STIR signal.
2. Coil bridging and coverage planning. Position dedicated body/spine phased-array coil elements end-to-end from vertex to mid-thigh (or feet), using integrated table coil elements where available. Plan the number of stations based on total coverage length and each coil element’s field of view — typically 5–7 stations for an average adult.
3. Localiser and station overlap programming. Acquire a whole-body coronal localiser and manually or automatically define station boundaries with a minimum 20% overlap between adjacent stations. This overlap is the primary defence against boundary geometric distortion and must never be reduced to save time. Many current platforms allow automated landmark-based station planning; even when automation is used, the technologist should visually confirm that the proposed overlap meets the 20% threshold before proceeding, since automated defaults are occasionally optimised for scan-time efficiency rather than diagnostic stitching quality.
4. Per-station shimming. Perform an independent 3D shim at each station rather than relying on a single whole-body shim, since B0 homogeneity varies significantly along the z-axis, particularly in the shoulders, pelvis, and thighs where tissue-air interfaces are abundant. A whole-body shim optimised for the thorax will frequently be suboptimal for the pelvis, producing exactly the kind of fat-suppression failure that mimics diffuse marrow pathology if left uncorrected.
5. Coronal STIR acquisition. Acquire coronal STIR at each station (TR ~4000–6000 ms, TE ~60 ms, TI ~150–170 ms at 1.5T) with slice thickness 5–6 mm, no gap, matched matrix and FOV across stations to preserve stitching geometry.
6. Axial STIR or T2 fat-sat through spine and pelvis. Add axial STIR or fat-saturated T2 through the spine and pelvis for improved conspicuity of focal lesions obscured by overlapping coronal structures, particularly in the posterior elements and sacrum. This axial supplement is especially valuable for lesions abutting the spinal canal, where coronal imaging alone can under-represent epidural extension.
7. Whole-body diffusion-weighted imaging (WB-DWI). Acquire free-breathing axial DWI at each station using b-values of 50 and 800–1000 s/mm² with STIR fat suppression, generating an ADC map and an inverted-grayscale maximum intensity projection (“PET-mimicking”) composite for lesion conspicuity and lymph node assessment. The inverted MIP display is particularly useful for referring clinicians accustomed to reading PET/CT, since the visual convention of bright lesions on a dark background transfers directly.
8. Axial/coronal T1 TSE (non-fat-sat). Acquire T1-weighted TSE at each station for anatomical correlation and marrow fat-signal baseline; this sequence is essential for distinguishing true infiltration (T1 hypointense) from red marrow reconversion (T1 intermediate but preserved fat signal on close inspection). It also provides the anatomical detail needed to confidently localise a DWI-avid focus back to a specific vertebral level or long-bone segment.
9. Optional post-infusion T1 Dixon station. When hepatic, splenic, or focal soft-tissue characterization is required (most often in lymphoma or when an indeterminate solid-organ lesion is identified), administer gadolinium per the contrast protocol below and repeat a targeted T1 Dixon acquisition through the relevant station(s) only — not the entire body — to control scan time and gadolinium dose. Confirm with the reporting radiologist before injection which specific station(s) require repeat acquisition, since this decision is clinical rather than purely technical.
10. Stitching, distortion correction, and quality review. Apply the vendor’s automated stitching and 3D gradient-nonlinearity distortion-correction algorithm before review. Inspect every station boundary on the composite coronal STIR and DWI-MIP images at the console before releasing the patient, specifically checking for step-artefact, signal discontinuity, or duplicated/missing anatomy at each junction. If any boundary is unsatisfactory, the affected station pair — not necessarily the entire examination — can often be re-acquired while the patient remains on the table, which is considerably more efficient than recalling the patient for a separate visit.

1.5T versus 3.0T comparison

Patient preparation and communication

A whole-body staging examination routinely occupies 35–45 minutes of table time, considerably longer than most single-region MRI studies, and this duration alone is a common source of motion-related artefact if the patient has not been adequately prepared beforehand. Explaining the multi-station structure to the patient in advance — that the table will move in stages and that brief periods of stillness are required at each stage — measurably reduces mid-examination movement compared with a generic “please stay still” instruction given only at the outset.

Claustrophobia management deserves specific mention because the extended duration of this protocol, combined with arms-at-sides positioning in a standard bore, can provoke anxiety in patients who tolerate shorter examinations without difficulty. Departments running a high volume of whole-body staging studies often find it worthwhile to offer a structured pre-scan walkthrough, wide-bore scanner scheduling where available, or anxiolytic premedication per local protocol for patients with a known history of claustrophobia, since a terminated or restarted examination costs considerably more departmental time than the preventive measures themselves.

Common causes of examination failure

Reviewing recurring failure patterns from departmental audits is one of the most effective ways to improve first-pass diagnostic quality on this protocol. The table below summarises the most frequently encountered causes of a technically inadequate whole-body staging examination, several of which overlap with — but are distinct from — the pitfall categories discussed later in this article.

Contrast media protocol

Whole-body MRI metastatic staging is, by design, a non-contrast-first protocol. The diagnostic backbone — STIR and WB-DWI — requires no gadolinium, which is precisely why the modality has become attractive for serial disease monitoring in myeloma and lymphoma, where patients may undergo staging and restaging examinations multiple times per year.

This design philosophy represents a genuine departure from most other protocols covered in this series, where contrast enhancement is central to the diagnostic question. In whole-body staging, the two non-contrast sequences do the overwhelming majority of the diagnostic work: STIR provides sensitive, non-specific detection of marrow water content changes, while DWI adds a functional, cellularity-based specificity layer that helps distinguish tumour from oedema or benign marrow change. Gadolinium, when added, answers a narrower question — usually organ-specific characterization — rather than contributing to the primary staging determination itself. Radiographers new to this protocol, having trained extensively on contrast-heavy examinations elsewhere in the department, sometimes default to requesting contrast “to be safe”; this instinct should be actively unlearned for this specific protocol, since unnecessary contrast administration adds cost, time, and gadolinium exposure without improving the primary staging answer.

Contrast is added selectively, not routinely, when one of the following applies: indeterminate hepatic or splenic lesion requiring dynamic characterization; suspected soft-tissue mass requiring enhancement pattern assessment; equivocal marrow signal where post-contrast T1 fat-sat can help distinguish viable tumour from treated/necrotic disease; or institutional lymphoma protocols that mandate a contrast-enhanced abdominal station for organ involvement staging.

Because gadolinium is used selectively rather than universally, it is essential that the radiographer confirms with the requesting radiologist or protocolling physician before the patient is on the table whether contrast is anticipated, since retrospective addition of a contrast station after the patient has already been positioned for a non-contrast workflow introduces significant time and workflow inefficiency.

Specific absorption rate and dose reduction

Whole-body STIR sequences are RF-intensive, using multiple 180° inversion and refocusing pulses across a long examination, and SAR management becomes a genuine constraint across five to seven consecutive stations rather than a single organ acquisition. SAR limits in this protocol are governed by whole-body averaged and partial-body exposure thresholds set out in IEC 60601-2-33 and adopted by the ICRP, EC Radiation Protection 185, and AAPM MR safety guidance.

Unlike a single-region examination where SAR headroom essentially resets between patients, whole-body staging accumulates RF energy continuously across the full table time, and most scanner platforms track a rolling whole-body-averaged SAR estimate over a 6- or 10-minute window rather than resetting it at each new station. A protocol that appears well within limits when a single station is tested in isolation can therefore still trigger forced parameter compromises — typically an automatic reduction in turbo factor or an increase in TR — once several consecutive STIR-heavy stations have been acquired back to back. Anticipating this cumulative effect at the protocol design stage, rather than reacting to it mid-examination, is what separates a smoothly run whole-body list from one punctuated by unplanned scanner-imposed delays.

The five strategies below are listed in the order most departments should apply them: parallel imaging and refocusing-flip-angle management first, since both preserve diagnostic contrast while directly lowering deposited energy, followed by workflow-level adjustments such as inter-station cooling pauses and selective contrast use that manage the cumulative examination-level SAR budget discussed above.

Five dose-reduction strategies

• Parallel imaging on every STIR station. Acceleration factors of 2–3 reduce the number of refocusing pulses required, directly lowering per-station SAR and shortening total examination time across a long multi-station survey. This should be treated as a default setting rather than a fallback applied only once SAR limits are reached, since applying it proactively avoids the console-imposed parameter compromises discussed above.
• Increased echo spacing within clinically acceptable limits. Modestly widening echo spacing in the STIR train reduces RF duty cycle without materially degrading fat-suppression uniformity, though excessive widening will begin to blur small marrow lesions and should be validated against a reference image set before being adopted as a standing departmental protocol change.
• Hyperecho / variable refocusing flip angle TSE. Reducing refocusing flip angles below 180° for later echoes in the train substantially lowers deposited energy while preserving diagnostic T2/STIR contrast, and is supported natively on most current-generation scanner platforms as a selectable sequence option.
• Inter-station cooling pauses. Programming brief pauses between stations allows cumulative SAR to dissipate, avoiding forced parameter compromises later in the examination; a pause of even 15–20 seconds at each station transition is often sufficient to reset the rolling SAR average meaningfully.
• Selective, not universal, contrast-enhanced Dixon stations. Limiting the T1 Dixon acquisition to the station(s) of clinical interest — rather than repeating it across the full body — reduces both gadolinium dose and additional RF-intensive acquisition time, compounding the benefit of the four strategies above rather than acting in isolation.

Top 10 pathologies detected on whole-body MRI

The ten conditions below represent the pathologies most frequently identified, or most frequently misidentified, on a whole-body staging examination. They span three broad categories that a systematic reporter should address separately: marrow-based malignant disease, benign marrow mimics that generate the majority of false-positive discussion, and structural spinal complications that carry independent clinical urgency regardless of the underlying oncologic diagnosis.

Beyond individual lesion recognition, the reporting radiologist’s task is to synthesise these findings into a structured staging category — MY-RADS for myeloma, or a tumour-appropriate response criterion for lymphoma and solid-organ metastatic disease — rather than simply listing lesions in isolation. A single missed benign mimic misclassified as malignant can shift a patient’s disease category and downstream treatment pathway just as materially as a missed true lesion, which is why the benign entries in the list above (numbers 6 and 8) warrant equal reporting attention to the unambiguously malignant ones.

Comparison with alternative staging modalities

Whole-body MRI does not exist in isolation as a staging tool, and understanding where it fits relative to FDG-PET/CT, technetium bone scintigraphy, and low-dose whole-body CT helps both radiologists and referring clinicians select the right modality for a given clinical question rather than defaulting to whichever is most familiar or most readily available. This section is intended as a practical reference for the multidisciplinary tumour board discussions where modality choice is most often debated, and where a radiologist’s ability to articulate the comparative strengths and limitations of each option in plain clinical language adds considerable value beyond the individual report.

Whole-body MRI versus FDG-PET/CT

For multiple myeloma and lymphoma, whole-body MRI and FDG-PET/CT demonstrate broadly comparable sensitivity for marrow and nodal disease, though the two modalities are not interchangeable in every scenario. PET/CT retains an advantage in detecting extramedullary disease with low anatomical conspicuity and in providing a single quantitative metabolic biomarker (SUVmax) for response assessment, while whole-body MRI offers superior soft-tissue and marrow anatomical detail, avoids radiotracer injection and its associated radiation dose, and is generally preferred for serial monitoring in younger patients or those requiring frequent restaging.

Whole-body MRI versus technetium bone scintigraphy

Bone scintigraphy remains widely available and inexpensive but is limited by its reliance on osteoblastic activity, meaning purely lytic or early marrow-infiltrative disease — the pattern typical of multiple myeloma — can be substantially under-detected. This limitation is precisely why international myeloma guidance has moved away from skeletal survey and scintigraphy toward cross-sectional modalities, with whole-body MRI or low-dose CT now recommended as first-line staging investigations.

Whole-body MRI versus low-dose whole-body CT

Low-dose CT offers faster acquisition and lower cost, and remains an acceptable alternative where MRI access is constrained, but it exposes the patient to ionizing radiation with each examination — a meaningful consideration for a patient population that may require serial restaging over years. CT also has materially lower sensitivity than MRI for detecting diffuse marrow infiltration that has not yet produced a discrete lytic lesion, since CT depends on cortical bone destruction becoming radiographically visible rather than directly imaging marrow water content.

Structured reporting and staging categories

Because whole-body MRI staging generates findings across dozens of anatomical regions in a single examination, unstructured free-text reporting is a recognised source of both omission and ambiguity. Most current guidance recommends a structured, region-by-region reporting template that separately addresses marrow findings, nodal chains, and — where imaged — solid organs, concluding with an explicit overall staging category rather than leaving the referring clinician to infer one from a list of individual findings.

For multiple myeloma, the MY-RADS framework provides a five-point pattern classification (normal, focal, diffuse, salt-and-pepper, and combined focal-on-diffuse) alongside a numerical scoring system for treatment response assessment on follow-up studies, allowing serial examinations to be compared using a shared vocabulary across different reporting radiologists and even different institutions. For lymphoma, structured reporting typically follows a nodal-region checklist analogous to that used in PET/CT reporting, cross-referencing each nodal station against the corresponding ADC value to support a Deauville-like functional response assessment where local protocols support it.

Consistency in reporting structure also directly supports the AI-assisted longitudinal tracking discussed later in this article: automated lesion-matching software performs considerably better when successive reports use a consistent anatomical nomenclature and region definition, underscoring that structured reporting is not merely an interpretive convenience but a technical enabler for future automation in this specific protocol.

Departments introducing structured reporting for the first time often find the transition easiest when a template is embedded directly in the reporting software as a fillable form, prompting the radiologist to address each anatomical region and conclude with an explicit staging category, rather than relying on the radiologist to remember and manually reproduce the structure in free text for every case. This small workflow investment pays dividends in reporting consistency across a department’s full radiologist roster, not just for the individual who designed the template.

Pitfalls — radiographers

The dominant technical pitfall named in the protocol specification for this examination is boundary geometric distortion — the misalignment, duplication, or omission of anatomy at the junction between adjacent table stations, arising from gradient nonlinearity toward the periphery of each station’s field of view combined with residual B0 inhomogeneity away from isocenter.

This pitfall deserves particular attention because, unlike many artefacts elsewhere in this series, it is largely preventable through workflow discipline rather than hardware upgrades. A technologist who consistently applies the full 20% overlap, verifies per-station shim quality, and inspects every junction before releasing the patient will rarely encounter a diagnostically significant boundary artefact, whereas a rushed workflow that treats these steps as optional will produce them routinely — often without the error becoming apparent until the radiologist is already midway through interpretation. The table below organises the recurring technical pitfalls in this protocol by category, description, and the specific mitigation that addresses each one.

Pitfalls — radiologists

The primary interpretation pitfall follows directly as the downstream consequence of the radiographer-level boundary distortion: misregistration artefact at station junctions being mistaken for a genuine focal marrow lesion or, conversely, a genuine lesion at a junction being obscured by stitching artefact.

The practical discipline that resolves most junction-related uncertainty is straightforward but frequently skipped under reporting time pressure: any suspicious finding that sits within roughly 2–3 cm of a visible station boundary should be re-examined on the individual, non-stitched source images for that station before being included in the report. The composite stitched dataset is an excellent tool for overview and lesion mapping, but it is the source images — not the composite — that should adjudicate any boundary-adjacent finding.

Pitfalls — non-radiology physicians

Referring physicians — haematologists, medical oncologists, and orthopaedic surgeons chief among them — interact with whole-body MRI reports without the benefit of having watched the acquisition or reviewed the source images, and several recurring misunderstandings arise specifically from that distance. The five pitfalls below are drawn from patterns seen repeatedly across oncology multidisciplinary meetings, where a report is discussed and acted upon by clinicians who did not generate it. Anticipating these patterns and addressing them proactively in report phrasing — rather than assuming the referring clinician will independently arrive at the correct interpretation — is one of the more effective ways a radiology department can reduce downstream confusion and unnecessary follow-up investigation.

Pitfall comparison summary

Viewed side by side, the three pitfall tiers form a chain: a scanning-level shortcut at station overlap creates the conditions for an interpretation-level misjudgement, which in turn can propagate into a clinical-level misunderstanding if the report language does not make the distinction between artefact and pathology explicit. Reviewing the three columns together is a useful exercise for departmental audit meetings, since a recurring clinical-level pitfall often traces back to a scanning-level root cause rather than a failure of clinical judgement in isolation.

AI and automation in whole-body MRI

Whole-body MRI staging generates an unusually large image volume per examination — often several thousand images across multiple sequences and stations — making it a natural target for AI-assisted workflows. Several FDA-cleared and CE-marked tools now support automated station stitching quality control, marrow segmentation, and lesion-conspicuity mapping on the DWI-MIP composite.

Beyond lesion detection, several vendors now offer automated distortion-quantification tools that flag a station junction for technologist review at the point of acquisition, before the patient leaves the table, rather than relying solely on visual inspection. Early adoption data suggests these tools meaningfully reduce the recall rate for repeat whole-body staging examinations, since a distortion problem caught and corrected at the point of acquisition avoids the workflow disruption of identifying it only during radiologist review, hours or days later.

Automated bone segmentation and longitudinal lesion-tracking software can flag new or enlarging STIR/DWI-avid foci between serial staging examinations, materially reducing radiologist read time for myeloma and lymphoma surveillance cohorts who may undergo three or more whole-body examinations per year. Distortion-correction algorithms applying 3D gradient nonlinearity maps at the reconstruction stage — rather than relying on overlap alone — are increasingly standard on current-generation scanners and directly reduce the boundary artefact discussed above.

As with every AI application discussed across this series, automation supports — but does not replace — the radiographer’s judgement in verifying stitching quality at the console and the radiologist’s correlation of AI-flagged foci against the full multiparametric dataset before a finding is reported.

Practical adoption of these tools varies considerably by department. Larger tertiary myeloma and lymphoma referral centres, where whole-body MRI volume is high enough to justify dedicated post-processing infrastructure, have generally moved furthest, integrating automated lesion tracking directly into the reporting workstation. Smaller departments performing whole-body staging less frequently may find manual, side-by-side comparison with the prior study remains the more practical approach until case volume and infrastructure investment reach a threshold that justifies dedicated software licensing and staff training.

Further reading

The following resources expand on contrast delivery precision, spine and skeletal MRI technique, and metastatic disease imaging referenced throughout this protocol.

1. 7 Proven Strategies for Optimizing MRI Sequences in 2026
2. Cervical Spine MRI Protocol: 10 Critical Steps
3. Gadolinium-Enhanced MRI in Brain Metastases: Enhancement Patterns and Protocols
4. 7 Expert Contrast-Enhanced Brain CT Protocol Steps
5. Top 100 Free Radiology Websites in 2026

Reducing artefacts with patients and parameters

The most critical scanning parameters that impact image quality in whole-body staging include the following four domains, each interacting with the multi-station geometry in ways that do not arise in single-region imaging. Because the same parameter set typically applies across every station, a suboptimal choice made once at protocol design stage is repeated five to seven times per examination — which is exactly why whole-body protocols deserve more careful upfront parameter validation than single-region examinations, where an isolated error affects only one acquisition.

1. Spatial resolution

Matrix size: increasing the matrix (frequency × phase) increases spatial resolution but decreases SNR as voxel size shrinks — a meaningful trade-off when the same matrix must be held constant across every station to preserve stitching geometry. Field of view: reducing FOV increases resolution but risks aliasing at station edges if not matched precisely across stations. Slice thickness: thinner slices improve resolution and reduce partial-volume averaging of small marrow lesions but reduce SNR and lengthen acquisition, a cost multiplied across five to seven stations. In practice, most departments settle on a single matrix, FOV, and slice-thickness combination validated once for their scanner and coil configuration, then lock it as a protocol default rather than adjusting it per patient, precisely because per-station variation is the single greatest threat to clean stitching.

2. Signal-to-noise ratio

Number of averages (NEX/NSA): increasing averages improves SNR but roughly doubles scan time per doubling — a cost that compounds rapidly across multiple stations, making average count one of the first parameters reviewed when total table time must be controlled. Receiver bandwidth: decreasing bandwidth boosts SNR but increases scan time and chemical-shift artefact, and lower bandwidth also lengthens the RF duty cycle, interacting directly with the SAR budget discussed above. Coil selection: dedicated, bridged phased-array surface coils dramatically outperform the body coil for SNR across every station and are non-negotiable for diagnostic-quality whole-body staging. Departments transitioning between coil generations should re-validate their SNR baseline whenever coil hardware changes, since even a nominally equivalent replacement coil can shift the achievable SNR enough to warrant a matrix or averages adjustment.

3. Image contrast

Repetition time (TR): the long TR used in STIR minimizes T1 contrast contamination, allowing the inversion pulse to control contrast via fat nulling rather than TR. Echo time (TE): the moderate TE in STIR balances T2 contrast against SAR and scan-time constraints. Inversion time (TI): the single most important contrast parameter in this protocol — TI must be accurately set to the field-strength-specific fat T1 (~150 ms at 1.5T) for reliable fat nulling across every station, since incorrect TI produces incomplete fat suppression that can mimic diffuse marrow abnormality. Flip angle in the DWI refocusing scheme also warrants attention, since suboptimal refocusing flip angles can introduce stimulated-echo contamination that subtly alters apparent ADC values, particularly at station boundaries where B1 homogeneity is already compromised.

4. Artefact control

Phase encoding direction: selecting phase direction to keep respiratory and cardiac motion artefact away from the spine and pelvis at thoracoabdominal stations. Flow compensation/gating: respiratory triggering at diaphragm-crossing stations minimizes blurring of liver, spleen, and lower lung base lesions. Parallel imaging: essential at every station both for SAR reduction (discussed above) and for controlling total examination time, discussed further in the next section. Beyond these three levers, careful attention to patient positioning — arms tucked symmetrically, midline alignment confirmed at every station reposition — reduces the incidence of wrap/aliasing artefact at the lateral margins of the field of view, which can otherwise be mistaken for a soft-tissue abnormality by a reviewer unfamiliar with the appearance of aliased anatomy.

Parallel imaging protocols and parameters

Parallel imaging is not optional in whole-body staging — it is the primary mechanism by which a five-to-seven station examination remains clinically feasible within a 35–45 minute table time while controlling SAR. The turbo factor (echo train length) in the STIR sequence interacts directly with both scan time and SAR, and must be balanced against parallel imaging acceleration at each field strength.

It is worth stating explicitly why this trade-off matters more here than in almost any other protocol in this series: a 10% scan-time saving on a single-region examination translates to perhaps 30–60 seconds, a marginal gain. The same 10% saving applied consistently across seven whole-body stations can translate to several minutes of total table time — enough, over a busy oncology imaging list, to accommodate an additional patient per day. Parallel imaging parameter selection in this protocol is therefore as much a departmental throughput decision as a pure image-quality one.

At higher turbo factors, image blurring along the phase-encoding direction increases due to T2 decay across the echo train, which can subtly reduce lesion conspicuity for small marrow foci — a further reason many centres favour 1.5T, where turbo factor can be pushed higher without the SAR penalty encountered at 3.0T.

A practical way to validate a new whole-body staging protocol before it goes live clinically is to run the full turbo-factor and parallel-imaging combination against a phantom or volunteer at every planned station position, confirming that neither SAR-driven parameter throttling nor unacceptable image blurring occurs at any point in the sequence of stations. Protocols validated only at a single “typical” station position can behave unexpectedly at stations closer to the shoulders or pelvis, where coil loading and B1 homogeneity differ meaningfully from the torso.

Quality assurance and departmental audit

Sustaining consistent whole-body staging quality over time requires more than a well-designed initial protocol; it requires ongoing departmental audit specifically targeted at the failure modes discussed throughout this article. A practical audit cycle reviews a sample of recent examinations against three criteria: whether the programmed station overlap met the 20% minimum on every junction, whether per-station shim quality was documented or visually verified, and whether any repeat acquisitions were required and, if so, why.

Tracking repeat-acquisition rate by technologist and by scanner over time is one of the more informative quality metrics available for this protocol, since it directly reflects adherence to the overlap and shimming discipline discussed in the technique section above. A department seeing a rising repeat rate on a specific scanner, independent of technologist, may be observing early gradient or shim-coil degradation that warrants engineering review before it affects diagnostic quality more broadly. Equally, a persistently elevated repeat rate concentrated in a subset of technologists points toward a training gap rather than a hardware issue, and should prompt targeted refresher training on station planning rather than a blanket protocol change.

A secondary but equally valuable audit metric is the proportion of examinations in which the optional contrast station was added after the patient was already positioned for a non-contrast workflow, since this figure directly reflects the quality of pre-booking communication discussed in the scheduling section below. Departments that reduce this figure over time typically do so not through technical changes but through improved referral documentation and booking checklists — a reminder that quality assurance in this protocol spans clinical workflow as much as pure image acquisition.

Scheduling and departmental throughput considerations

The 35–45 minute table time of a whole-body staging examination has direct scheduling implications that many departments underestimate when first adding this protocol to their case mix. Unlike a 15–20 minute single-region MRI, a whole-body staging slot cannot easily absorb a delayed start without cascading through the remainder of the day’s list, and departments running a mixed caseload of routine and whole-body examinations benefit from grouping whole-body slots at the start or end of a scanner’s daily schedule rather than interspersing them between shorter studies.

Booking accuracy also matters more for this protocol than for most others in the series, since the coverage extent (mid-thigh versus full lower limb), the anticipated need for a contrast station, and any sedation requirements for paediatric patients must all be known before the patient arrives — retrospectively discovering a contrast requirement partway through a non-contrast-planned slot introduces exactly the kind of workflow disruption discussed in the contrast media protocol section above. A structured pre-booking checklist, completed by the referring clinician or booking coordinator, meaningfully reduces same-day protocol changes and the delays they cause.

Special populations

Certain patient groups warrant specific protocol adjustments beyond the standard adult staging workflow described above.

Paediatric patients

Whole-body MRI is particularly valuable in paediatric oncology — for neuroblastoma, lymphoma, and certain sarcomas — precisely because it avoids the cumulative radiation exposure of repeated CT or PET/CT in a population with a long remaining lifespan and correspondingly greater lifetime radiation risk. Station planning must account for the smaller body habitus, which typically reduces the total number of stations required but places greater demands on precise coil bridging given the reduced margin for positioning error. Sedation or general anaesthesia is more frequently required in younger children, and the extended table time of this protocol should be weighed carefully against that consideration when planning the anaesthetic approach.

Pregnant patients

Whole-body MRI without gadolinium is generally considered acceptable in pregnancy when clinically indicated and when the information cannot be otherwise obtained, consistent with general MRI safety guidance for the gravid patient. Gadolinium-based contrast is avoided in pregnancy wherever possible, reinforcing the value of the non-contrast STIR/DWI backbone of this protocol, which typically answers the primary staging question without requiring the selective contrast station discussed earlier.

Renal impairment

Patients with significant renal impairment are, by the same logic, particularly well served by the non-contrast-first design of this protocol. Where the optional contrast station is being considered in a patient with reduced renal function, standard institutional gadolinium safety screening applies, and the referring team should be consulted on whether the additional organ-specific information justifies proceeding, deferring, or substituting an alternative non-contrast characterization approach.

Conclusion

Whole-body MRI metastatic staging succeeds or fails on geometric fidelity across multiple table stations rather than on any single sequence’s raw contrast performance. The STIR and WB-DWI backbone of this protocol delivers sensitivity for skeletal and nodal metastatic disease that rivals or exceeds bone scintigraphy and, for many indications, complements FDG-PET/CT — all without ionizing radiation and, in most cases, without gadolinium. The technical discipline required to achieve this lies almost entirely in station overlap, per-station shimming, and rigorous console-side quality review before the patient leaves the table.

The pitfall framework threading through this article — boundary distortion for radiographers, junction pseudolesions and marrow-signal misinterpretation for radiologists, and premature reassurance or misordered restaging for referring physicians — reflects a single underlying truth: whole-body MRI is a stitched composite of many smaller acquisitions, and every discipline involved must understand where those seams are and what artefacts they can produce. Applied consistently, this protocol delivers reproducible, radiation-free staging and restaging across the full arc of a patient’s oncologic care.

As adoption continues to grow across myeloma, lymphoma, and solid-tumour metastatic pathways, the departments that get the most diagnostic value from this examination will be those that treat it as a distinct technical discipline in its own right — not simply a longer version of a routine spine or pelvis MRI — with dedicated staff training on station planning, shimming workflow, and junction-aware reporting. The investment in that training is returned many times over across a patient’s serial imaging journey, where a single well-executed baseline staging examination becomes the reference point against which every subsequent restaging study is measured.

References